Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Dow
Moodys
Mallinckrodt
Medtronic

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,365,205

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,365,205 protect, and when does it expire?

Patent 7,365,205 protects SAVAYSA and is included in one NDA.

This patent has sixty patent family members in twenty-five countries.

Summary for Patent: 7,365,205
Title:Diamine derivatives
Abstract: A compound represented by the general formula (1): Q.sup.1-Q.sup.2-T.sup.0-N(R.sup.1)-Q.sup.3-N(R.sup.2)-T.sup.1-Q.sup.4 (1) wherein R.sup.1 and R.sup.2 are hydrogen atoms or the like; Q.sup.1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q.sup.2 is a single bond or the like; Q.sup.3 is a group ##STR00001## in which Q.sup.5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T.sup.0 and T.sup.1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
Inventor(s): Ohta; Toshiharu (Tokyo, JP), Komoriya; Satoshi (Tokyo, JP), Yoshino; Toshiharu (Tokyo, JP), Nagamochi; Masatoshi (Tokyo, JP), Ono; Makoto (Tokyo, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:10/481,262
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,365,205
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,365,205

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-002 Jan 8, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,365,205

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-187105Jun 20, 2001
Japan2001-243046Aug 9, 2001
Japan2001-311808Oct 9, 2001
Japan2001-398708Dec 28, 2001
PCT Information
PCT FiledMarch 20, 2002PCT Application Number:PCT/JP02/02683
PCT Publication Date:January 03, 2003PCT Publication Number: WO03/000657

International Family Members for US Patent 7,365,205

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 036102   Start Trial
Argentina 099165   Start Trial
Austria 556066   Start Trial
Australia 2002328596   Start Trial
Australia 2002346300   Start Trial
Brazil 0210541   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
AstraZeneca
Colorcon
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.